Nanoscale Reports

RESEARCH ARTICLE

DOI:10.26524/nr.8.5

8(2) (2025) 5-8

OPEN ACCESS

Nanoparticles as Antimicrobial Agents: A Promising Solution Against Multidrug Resistance

Pavan T.K [a], Niranjan Raj.S [a], Syed Baker [a]*

Abstract

Multidrug-resistant (MDR) pathogens pose a significant threat to global health, rendering many conventional antibiotics ineffective and leading to prolonged infections, higher mortality rates, and increased healthcare costs. As resistance mechanisms continue to evolve, alternative approaches are urgently needed. Nanoparticles (NPs), due to their unique physicochemical properties, have emerged as a promising solution to combat MDR infections. This paper explores the potential of nanoparticles as antimicrobial agents, focusing on their mechanisms of action, types, and applications in fighting bacterial, fungal, and viral resistance. Metal nanoparticles such as silver, copper, and gold, along with metal oxides, carbon-based materials, and polymeric hybrids, demonstrate potent antimicrobial activity through mechanisms including membrane disruption, generation of reactive oxygen species, and interference with microbial DNA and enzymes. Additionally, nanoparticles can be engineered to enhance drug delivery, overcoming challenges such as biofilm formation and poor antibiotic penetration. Despite their promise, several challenges remain, including toxicity concerns, nanoparticle resistance, and regulatory hurdles. Future innovations in multifunctional and smart nanoparticles, along with green synthesis techniques, hold the potential to enhance therapeutic outcomes and reduce side effects. This paper concludes that nanoparticles represent a vital tool in the fight against MDR pathogens, offering new avenues for antimicrobial therapy, but further research, clinical trials, and regulatory frameworks are necessary for their widespread clinical application.

Keywords: Nanoparticles, Multidrug-Resistant Pathogens, Antimicrobial Nanomaterials, Metal Nanoparticles.

Author Affiliation: [1]Department of Studies in Microbiology, Karnataka State Open University, Mysore

Corresponding Author: Syed Baker. Department of Studies in Microbiology, Karnataka State Open University, Mysore

Email: syedbaker3@gmail.com

How to cite this article: Pavan T.K, Niranjan Raj. S, Syed Baker, Nanoparticles as Antimicrobial Agents: A Promising Solution Against Multidrug Resistance, Nanoscale Reports, 8(2) 2025 5-8. Retrieved from https://nanoscalereports.com/index.php/nr/article/view/103

Received: 30 December 2024 Revised: 26 April 2025 Accepted: 14 June 2025

I.INTRODUCTION

Multidrug-resistant (MDR) pathogens are one of the most significant threats to global public health, causing severe infections that are difficult to treat with conventional antibiotics. The rise of antibiotic resistance, driven by overuse and misuse of antimicrobial agents, is rendering many existing therapies ineffective. MDR bacteria, fungi, and viruses are capable of evading the mechanisms of action of multiple drug classes, leading to increased morbidity, mortality, and healthcare costs. Traditional antibiotic development has slowed due to the complexity of resistance mechanisms and the challenges of discovering new compounds. In response to this growing crisis, nanotechnology offers a promising solution (Basavegowda and Baek 2021). Nanoparticles (NPs) possess unique properties, such as high surface area, small size, and reactivity, which enhance their ability to interact with microbial cells. These properties enable nanoparticles to exhibit potent antimicrobial activity against a broad spectrum of pathogens, including those resistant to conventional antibiotics. Additionally, nanoparticles can be engineered to enhance their efficacy, selectivity, and stability, making them suitable for use in various therapeutic applications (Adeniji et al., 2022). This paper explores the potential of nanoparticles as antimicrobial agents, examining their mechanisms of action, types, and applications in combating MDR pathogens. We also discuss the challenges associated with their use and the future directions for nanoparticle-based therapies in the fight against antibiotic resistance

2. MECHANISMS OF MULTIDRUG RESISTANCE

Multidrug resistance (MDR) is the ability of microorganisms to resist the effects of multiple classes of antibiotics, often making infections difficult or impossible to treat. MDR bacteria employ various mechanisms to evade the action of antimicrobial agents. One major mechanism is the active efflux of antibiotics via membrane transport proteins, which reduce the intracellular concentration of drugs. Another common mechanism is the enzymatic degradation or modification of antibiotics, where bacteria produce enzymes like β-lactamases that break down antibiotics before they can exert their effects (Mateo and Jimenez 2022). Changes in membrane permeability can also contribute to resistance, as bacteria alter their cell wall structure, reducing the uptake of drugs. Additionally, some bacteria acquire resistance genes through horizontal gene transfer, a process in which genetic material, including resistance traits, is passed between bacteria. These mechanisms are often facilitated by the presence of mobile genetic elements, such as plasmids and transposons (Baker et al., 2013). As a result, MDR bacteria can rapidly adapt to new antimicrobial agents, complicating treatment options. Fungi and viruses also exhibit resistance through similar mechanisms, including mutations in target sites and biofilm formation. The spread of resistance poses a serious challenge to global health systems and underscores the need for innovative approaches, such as nanoparticles, to combat infections and prevent further resistance development (Matar et al., 2018).

3. Types of Nanoparticles Used as Antimicrobial Agents

3.1 Metal Nanoparticles

Metal nanoparticles, particularly silver (AgNPs), copper (CuNPs), and gold (AuNPs), have demonstrated significant antimicrobial properties. Silver nanoparticles, for instance, are among the most widely studied due to their broad-spectrum activity against bacteria, fungi, and viruses. The antimicrobial effects of metal nanoparticles are primarily attributed to their ability to generate reactive oxygen species (ROS), which cause oxidative stress and damage cellular components like membranes, proteins, and DNA. Additionally, metal ions released from nanoparticles can interact with microbial cell surfaces, disrupting cell function (Hetta et al., 2023). Copper nanoparticles have similar antimicrobial properties, and their effectiveness is attributed to the release of Cu ions, which can penetrate bacterial cell membranes, disrupting cellular processes. Gold nanoparticles, while less reactive than silver or copper, exhibit antimicrobial effects through surface chemistry modifications that enable them to bind to microbial surfaces. The ability to tailor metal nanoparticle size, shape, and surface charge further enhances their antimicrobial potency. Despite their effectiveness, concerns about potential toxicity to human cells and the environment remain, necessitating careful evaluation of their use in medical applications. Metal nanoparticles hold great promise in overcoming MDR pathogens, offering a novel approach to treating infections that are resistant to conventional antibiotics (Balestri et al., 2023).

3.2 Metal Oxide Nanoparticles

Metal oxide nanoparticles, including zinc oxide (ZnO) and titanium dioxide (TiO_2), have garnered attention for their antimicrobial properties, particularly under light activation. ZnO nanoparticles exhibit potent antibacterial, antifungal, and antiviral activity, primarily due to the generation of ROS upon exposure to ultraviolet (UV) light. These ROS can damage microbial cell membranes, proteins, and nucleic acids, leading to cell death. ZnO nanoparticles are also known to disrupt the microbial membrane integrity, facilitating the entry of metal ions that further contribute to their antimicrobial effects (Hadiya et al., 2022). Similarly, TiO_2 nanoparticles possess photocatalytic properties that enable them to degrade a wide range of organic pollutants, including microbial cell components. When activated by UV light, TiO_2 nanoparticles generate ROS that can kill or inactivate a variety of microorganisms. In addition to their antimicrobial activity, these nanoparticles are relatively nontoxic to humans, making them suitable for use in medical and environmental applications. The challenge, however, lies in their efficient activation under natural light conditions and the potential for nanoparticle aggregation, which can reduce their effectiveness. Despite these challenges, metal oxide nanoparticles remain a promising tool in the fight against MDR pathogens, especially when combined with other nanoparticles or incorporated into novel drug delivery systems (Baptista et al., 2018).

3.3 Carbon-Based Nanoparticles

Carbon-based nanoparticles, such as graphene oxide (GO) and carbon nanotubes (CNTs), are another class of nanomaterials with remarkable antimicrobial properties. Graphene oxide, a derivative of graphene, has gained attention due to its large surface area, high mechanical strength, and ability to interact with bacterial membranes. GO nanoparticles can adsorb onto the surface of microbial cells, disrupting membrane integrity and causing leakage of intracellular contents. Additionally, the sharp edges of GO sheets can physically pierce bacterial membranes, leading to cell death. Carbon nanotubes, with their cylindrical structure, can also interact with microbial cells, either by inserting into the membrane or by facilitating the transport of antimicrobial agents across the cell wall (Hadiya et al., 2022). Both GO and CNTs exhibit broad-spectrum antimicrobial activity against a wide range of bacteria, fungi, and viruses. Furthermore, carbon-based nanoparticles can be functionalized with various antimicrobial agents or drugs, enhancing their effectiveness. The biocompatibility and low toxicity of carbon-based nanoparticles to mammalian cells make them promising candidates for antimicrobial therapies. However, challenges related to their synthesis, stability, and potential environmental impact must be addressed before widespread use (Gupta et al., 2017).

3.4 Polymeric and Hybrid Nanoparticles

Polymeric and hybrid nanoparticles are versatile nanomaterials that can be engineered to combine the advantages of various materials, such as metals, polymers, and ceramics. These nanoparticles can be designed for targeted drug delivery and controlled release, offering improved therapeutic efficacy in the treatment of MDR infections. Biodegradable polymers, such as poly (lactic-co-glycolic acid) (PLGA) and chitosan, are commonly used as matrices for nanoparticle formation due to their biocompatibility and ability to encapsulate antimicrobial agents. Hybrid nanoparticles, which combine metal nanoparticles with polymeric or carbon-based materials, offer enhanced stability, controlled release, and synergistic antimicrobial effects. For example, silver nanoparticles can be embedded in a polymeric matrix, allowing for sustained release over time, reducing the risk of bacterial resistance (Matar et al., 2018). These hybrid systems can also be functionalized with targeting ligands, enabling them to selectively interact with specific pathogens, improving treatment outcomes. Additionally, polymeric nanoparticles can enhance the solubility and bioavailability of poorly water-soluble antibiotics, further expanding the range of antimicrobial agents that can be used effectively. The ability to engineer these nanoparticles for specific applications holds great potential in the development of next-generation antimicrobial therapies (Rabiee et al., 2022).

4. MECHANISMS OF ACTION OF NANOPARTICLES AS ANTIMICROBIAL AGENTS

The antimicrobial mechanisms of nanoparticles are diverse and depend on their size, shape, composition, and surface properties. One primary mode of action is the physical disruption of microbial membranes. Due to their small size, nanoparticles can penetrate bacterial cell walls, causing membrane damage and leakage of cellular contents, ultimately leading to cell death. Nanoparticles can also generate reactive oxygen species (ROS), which induce oxidative stress within the microbial cell. ROS can damage key cellular components such as lipids, proteins, and nucleic acids, leading to irreversible cellular damage and death (Rai et al., 2012). Another important mechanism involves the interaction of nanoparticles with microbial DNA and enzymes (Syed et al., 2016). Metal nanoparticles, such as silver, can bind to bacterial DNA and inhibit replication, while other nanoparticles

may interfere with enzymatic processes crucial for microbial survival. Nanoparticles can also act as adjuvants to enhance the activity of traditional antibiotics. By disrupting bacterial defenses or enhancing drug uptake, nanoparticles can restore the efficacy of antibiotics against resistant strains. Additionally, the ability of nanoparticles to accumulate in biofilms—protective layers that are often formed by resistant bacteria—further enhances their antimicrobial activity. These multi-faceted mechanisms make nanoparticles a powerful tool in the fight against MDR pathogens (Shaikh et al., 2019).

5. APPLICATIONS OF NANOPARTICLES IN COMBATING MDR PATHOGENS

Nanoparticles are being increasingly explored for their potential in treating infections caused by multidrug-resistant (MDR) pathogens. In particular, they offer a novel approach to combating bacterial, fungal, and viral infections that are resistant to conventional antibiotics. For example, silver nanoparticles (AgNPs) have shown remarkable efficacy against a wide range of MDR bacteria, including Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. AgNPs disrupt bacterial cell membranes, induce oxidative stress, and can penetrate biofilms, making them effective against tough, drug-resistant strains. Additionally, nanoparticles can be used in combination therapies to potentiate the action of existing antibiotics (Matar et al., 2018). This approach has been shown to restore antibiotic activity in resistant strains, providing an alternative to developing new antibiotics from scratch. In fungal infections, nanoparticles like ZnO and TiO_2 have demonstrated antifungal properties against pathogens such as Candida albicans and Aspergillus spp. Furthermore, nanoparticles can be engineered to deliver antimicrobial agents directly to the site of infection, enhancing the therapeutic effect while minimizing side effects. Preclinical and clinical studies are increasingly supporting the use of nanoparticles as adjunctive therapies for MDR infections, especially in treating chronic, nosocomial, and biofilm-associated infections. The versatility of nanoparticles, combined with their ability to overcome drug resistance, positions them as a promising solution in the fight against MDR pathogens (Singh et al., 2014).

6. Challenges in the Use of Nanoparticles for Antimicrobial Therapy

While nanoparticles hold great promise as antimicrobial agents, several challenges must be addressed before their widespread use in clinical settings. One of the primary concerns is the potential toxicity of nanoparticles to human cells and the environment. Although nanoparticles are often more selective toward microbial cells due to differences in membrane composition, their small size and reactivity can lead to unintended interactions with human tissues, potentially causing cytotoxicity, inflammation, or organ damage. Moreover, the potential for bioaccumulation of nanoparticles in living organisms raises concerns about long-term exposure and environmental impact (Basavegowda and Baek 2021). Regulatory bodies face difficulties in establishing guidelines for nanoparticle safety, as there is still a lack of standardized testing protocols and sufficient data on the long-term effects of nanoparticles. Another significant challenge is the development of nanoparticle resistance. Just as bacteria develop resistance to antibiotics, there is the potential for microorganisms to develop resistance to nanoparticles through mechanisms such as membrane modifications or the production of biofilms. This possibility necessitates ongoing monitoring and the development of new, more effective nanoparticles to circumvent resistance. Additionally, scaling up the production of nanoparticles from laboratory settings to commercial applications presents logistical and cost-related challenges. These factors highlight the need for careful evaluation, robust regulatory frameworks, and continued research into the safe and effective use of nanoparticles in antimicrobial therapy (Lee et al., 2019).

7. FUTURE DIRECTIONS AND INNOVATIONS

The future of nanoparticles as antimicrobial agents holds exciting possibilities, particularly with advancements in nanotechnology. Researchers are focusing on developing multifunctional nanoparticles that can not only combat microbial resistance but also deliver drugs in a controlled and targeted manner. This approach would maximize therapeutic efficacy while minimizing side effects. One promising direction is the integration of nanoparticles with other antimicrobial strategies, such as the use of antimicrobial peptides or enzymes, to create hybrid materials with synergistic effects. Another area of interest is the development of smart nanoparticles that can respond to environmental triggers, such as pH or temperature changes, allowing for on-demand release of antimicrobial agents (Valenti et al., 2022). Moreover, the use of green synthesis methods for producing nanoparticles is gaining traction, as these processes are environmentally friendly, cost-effective, and less toxic than traditional methods. The emergence of nanocarriers for targeted drug delivery, particularly to sites of infection such as biofilms or tissues with poor antibiotic penetration, is also a significant area of innovation. By focusing on safer, more sustainable, and effective nanoparticle formulations, researchers are working toward overcoming the limitations currently facing nanoparticle-based antimicrobial therapies. As the field progresses, interdisciplinary collaboration, clinical trials, and regulatory updates will be crucial to unlocking the full potential of nanoparticles in combatting MDR pathogens (Rai et al., 2012).

8. CONCLUSION

Nanoparticles represent a promising alternative to conventional antibiotics in the fight against multidrug-resistant (MDR) pathogens. Their unique properties—such as small size, high surface area, and ability to interact with microbial cells—allow them to disrupt bacterial membranes, generate reactive oxygen species (ROS), and interfere with essential cellular processes, offering multiple mechanisms of action that can overcome resistance. The various types of nanoparticles, including metal nanoparticles (such as silver and copper), metal oxides, carbon-based materials, and polymeric nanoparticles, provide diverse approaches for combating a wide range of infections. However, challenges such as potential toxicity, resistance development, and environmental concerns must be addressed through continued research and the development of safe, sustainable nanoparticle formulations. The future of nanoparticle-based antimicrobial therapies lies in the creation of multifunctional, smart nanoparticles capable of targeted delivery and controlled release, enhancing their therapeutic efficacy. With advancements in nanotechnology, nanoparticles are poised

to play a critical role in addressing the global challenge of MDR infections, offering hope for more effective treatments in the near future. Continued collaboration among researchers, clinicians, and regulatory bodies will be essential in realizing the full potential of nanoparticles in antimicrobial therapy.

Acknowledgemet

Nill

Funding

No funding was received to carry out this study.

References

1. Adeniji, O. O., Nontongana, N., Okoh, J. C., & Okoh, A. I. (2022). The potential of antibiotics and nanomaterial combinations as therapeutic strategies in the management of Multidrug-resistant infections: A Review. International Journal of Molecular Sciences, 23(23), 15038. https://doi.org/10.3390/ijms232315038
2. AlMatar, M., Makky, E. A., Var, I., & Koksal, F. (2018). The role of nanoparticles in the inhibition of multidrug-resistant bacteria and biofilms. Current Drug Delivery, 15(4), 470–484. https://doi.org/10.2174/1567201815666171207163504
3. Baker S, Rakshith D, Kavitha KS, Santosh P, Kavitha HU, Rao Y, Satish S (2013) Plants: emerging as nanofactories towards facile route in synthesis of nanoparticles. Bioimpacts 3:111–117
4. Balestri, A., Cardellini, J., & Berti, D. (2023). Gold and silver nanoparticles as tools to combat multidrug-resistant pathogens. Current Opinion in Colloid & Interface Science, 66, 101710. https://doi.org/10.1016/j.cocis.2023.101710
5. Baptista, P. V., McCusker, M. P., Carvalho, A., Ferreira, D. A., Mohan, N. M., Martins, M., & Fernandes, A. R. (2018). Nano-strategies to fight multidrug resistant bacteria—"a battle of the Titans." Frontiers in Microbiology, 9. https://doi.org/10.3389/fmicb.2018.01441
6. Basavegowda, N., & Baek, K.-H. (2021). Multimetallic nanoparticles as alternative antimicrobial agents: Challenges and perspectives. Molecules, 26(4), 912. https://doi.org/10.3390/molecules26040912
7. Gupta, A., Saleh, N. M., Das, R., Landis, R. F., Bigdeli, A., Motamedchaboki, K., Rosa Campos, A., Pomeroy, K., Mahmoudi, M., & Rotello, V. M. (2017). Synergistic antimicrobial therapy using nanoparticles and antibiotics for the treatment of multidrug-resistant bacterial infection. Nano Futures, 1(1), 015004. https://doi.org/10.1088/2399-1984/aa69fb
8. Hadiya, S., Ibrahem, R., Abd El-Baky, R., Elsabahy, M., & Aly, S. (2022). Nanoparticles based combined antimicrobial drug delivery system as a solution for bacterial resistance. Bulletin of Pharmaceutical Sciences. Assiut, 45(2), 1121–1141. https://doi.org/10.21608/bfsa.2022.271825
9. Hetta, H. F., Ramadan, Y. N., Al-Harbi, A. I., A. Ahmed, E., Battah, B., Abd Ellah, N. H., Zanetti, S., & Donadu, M. G. (2023). Nanotechnology as a promising approach to combat multidrug resistant bacteria: A comprehensive review and future perspectives. Biomedicines, 11(2), 413. https://doi.org/10.3390/biomedicines11020413
10. Lee, N.-Y., Ko, W.-C., & Hsueh, P.-R. (2019a). Nanoparticles in the treatment of infections caused by multidrug-resistant organisms. Frontiers in Pharmacology, 10. https://doi.org/10.3389/fphar.2019.01153
11. Lee, N.-Y., Ko, W.-C., & Hsueh, P.-R. (2019b). Nanoparticles in the treatment of infections caused by multidrug-resistant organisms. Frontiers in Pharmacology, 10. https://doi.org/10.3389/fphar.2019.01153
12. Mateo, E. M., & Jiménez, M. (2022). Silver nanoparticle-based therapy: Can it be useful to combat multi-drug resistant bacteria? Antibiotics, 11(9), 1205. https://doi.org/10.3390/antibiotics11091205
13. Rabiee, N., Ahmadi, S., Akhavan, O., & Luque, R. (2022). Silver and gold nanoparticles for antimicrobial purposes against multi-drug resistance bacteria. Materials, 15(5), 1799. https://doi.org/10.3390/ma15051799
14. Rai, M. K., Deshmukh, S. D., Ingle, A. P., & Gade, A. K. (2012). Silver nanoparticles: The powerful nanoweapon against Multidrug-resistant bacteria. Journal of Applied Microbiology, 112(5), 841–852. https://doi.org/10.1111/j.1365-2672.2012.05253.x
15. Shaikh, S., Nazam, N., Rizvi, S. M., Ahmad, K., Baig, M. H., Lee, E. J., & Choi, I. (2019). Mechanistic insights into the antimicrobial actions of metallic nanoparticles and their implications for multidrug resistance. International Journal of Molecular Sciences, 20(10), 2468. https://doi.org/10.3390/ijms20102468
16. Syed B, Prasad MN, Satish S (2016) Synthesis and characterization of silver nanobactericides produced by Aneurinibacillus migulanus 141, a novel endophyte inhabiting Mimosa pudica L. Arabian Journal of Chemistry.
17. Valenti, G. E., Alfei, S., Caviglia, D., Domenicotti, C., & Marengo, B. (2022). Antimicrobial peptides and cationic nanoparticles: A broad-spectrum weapon to fight multi-drug resistance not only in bacteria. International Journal of Molecular Sciences, 23(11), 6108. https://doi.org/10.3390/ijms23116108